This study is designed to retrospectively validate the colorectal liver metastasis recurrence predictor in an ongoing Phase II trial involving active immunotherapy of patients after complete resection of colorectal liver metastases. The use of gene expression analysis provides an opportunity to individualize therapy and identify those patients who will derive the most benefit from immunotherapy. $20,000